**Supplemental Digital Content 1: Patient selection for analysis.**

Total PODI database 2,603

Excluded 246 not matching inclusion criteria

21 <18 years of age at time of decentralization

6 <6 months on ART at time of decentralization

22 on 2nd line ART at time of decentralization

197 with CD4 ≤250 cells/μl

Excluded 98 not providing follow-up time

2 transferred out at same day they were decentralized

96 missing decentralization date

Outcomes: 1 (1.0%) death

3 (3.1%) transferred out

7 (7.3%) LTFU

85 (88.5%) retained

Retained for analysis 2,259

ART: Anti-retroviral therapy. CD4: Cluster of differentiation type 4. LTFU: Loss to follow-up.

**Supplemental Digital Content 2: Patient characteristics.**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Patients**  (N= 2,259) | |
| **Characteristics** | | **n** | **%** a |
| **Sex** | | | |
|  | male | 539 | 23.9 |
|  | female | 1,720 | 76.1 |
| **Age** b *(years)* | | | |
|  | >=18 - <30 | 122 | 5.4 |
|  | >=30 - <40 | 543 | 24.0 |
|  | >=40 - <50 | 941 | 41.7 |
|  | >=50 | 651 | 28.8 |
|  | *missing* | 2 | 0.1 |
|  | Mean (SD) | 45.0 (9.3) | |
| **Marital status** c | | | |
|  | single | 526 | 23.4 |
|  | separated | 271 | 12.0 |
|  | married | 917 | 40.6 |
|  | widowed | 521 | 23.1 |
|  | *missing* | *24* | *1.1* |
| **Educational level** c | | | |
|  | none | 83 | 3.7 |
|  | primary | 304 | 13.5 |
|  | secondary | 1,527 | 67.6 |
|  | tertiary | 301 | 13.3 |
|  | *missing* | *44* | *2.1* |
| **NNRTI used** b | | | |
|  | EFV | 411 | 18.2 |
|  | NVP | 1,848 | 81.8 |
| **NRTI used** b | | | |
|  | D4T-based | 1,335 | 59.1 |
|  | not D4T-based | 924 | 40.9 |
| **Time on ART** b *(years)* | | | |
|  | <3 | 914 | 40.5 |
|  | >=3 - <=6 | 500 | 22.1 |
|  | >6 | 845 | 37.4 |
|  | Mean (SD) | 4.4 (2.6) | |
| **CD4 count** b *(cells/µl)* | | | |
|  | >250 - <=350 | 312 | 13.8 |
|  | >350 - <=500 | 631 | 27.9 |
|  | >500 | 1,315 | 58.2 |
|  | *missing* | *1* | *<0.1* |
|  | Median (IQR) | 545.5 (407- 727) | |
| **Body Mass Index** b | | | |
|  | <18.5 | 206 | 9.1 |
|  | >=18.5 - <25 | 1,281 | 56.7 |
|  | >=25 | 626 | 27.7 |
|  | *missing* | *146* | *6.5* |
|  | Mean (SD) | 23.4 (4.4) | |
| **Distance home to PODI** *(min)* | | | |
|  | <15 | 839 | 37.1 |
|  | >=15 - <=45 | 794 | 35.2 |
|  | >45 | 571 | 25.3 |
|  | *missing* | *55* | *2.4* |
| **Decentralization site** | | | |
|  | central | 1,056 | 46.8 |
|  | east | 854 | 37.8 |
|  | west | 349 | 15.5 |

a Percentage of column total.

b At time of decentralization. Non-d4T options were AZT, 3TC, and TDF.

c At time of ART initiation.

%: percentage. 3TC: Lamivudine. ART: Anti-retroviral therapy. AZT: Zidovudine. CD4: Cluster of differentiation type 4. D4T: Stavudine. EFV: Efavirenz. IQR: Inter-quartile range. N: Total number of patients. n: Sub-total number of patients. NNRTI: Non-nucleoside reverse-transcriptase inhibitor. NRTI: Nucleoside reverse-transcriptase inhibitor. NVP: Nevirapine. PODI: Poste de distribution communautaire. SD: Standard deviation. TDF: Tenofovir.